InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,652.00
(
0.06%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,848.63
(
0.09%
)
Post# of 648882
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Tuff-Stuff

Send PM Follow Ignore
Followers 219
Posts 247348
Boards Moderated 2
Alias Born 04/06/2006

Tuff-Stuff

Re: None

Monday, 01/26/2015 8:14:21 AM

Monday, January 26, 2015 8:14:21 AM

Post# of 648882
The FDA grants Fast Track status to BioCryst Pharmaceuticals' (NASDAQ:BCRX) plasma kallikrein inhibitor BCX4161 for the treatment of hereditary angioedema. The product candidate is currently in Phase 2/3 development. Clinical trial results are expected by the end of this year.Fast Track designation allows for more frequent interactions with the FDA review team and a rolling review of the New Drug Application (NDA).

Pray for A Pain Free Day!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up